Phase 4
N=54
Comparison of Visual Field Assessments Between Three Perimeters
Glaucoma
Bottom Line
View on ClinicalTrials.gov: NCT06539715 ↗Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Total Acquisition Time (Both Eyes) — 4.44; 7.34; 7.71 minutes
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Visual field assessment (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Gainesville Eye Associates
- Primary completion
- Mar 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Acquisition Time (Both Eyes) |
4.44; 7.34; 7.71 | — |
| SECONDARY Mean Deviation (MD) |
-3.16; -3.28; -4.22 | — |
| SECONDARY Pattern Standard Deviation (PSD) |
4.78; 4.22; 4.51 | — |
| SECONDARY Foveal Threshold (FT) |
31.40; 34.71; 27.61 | — |
| SECONDARY Patient Questionnaire |
53; 28; 45; 48; 16; 40 | — |
Summary
A single center, prospective, randomized, comparative study of visual field assessments between the TEMPO, VisuALL, and HFA perimeters. Subjects will be assessed at 1 visit. Clinical evaluations will include MD, PSD, FT, VFI, OCT, and a questionnaire.
Eligibility Criteria
Inclusion Criteria
- Adult patients with best-corrected visual outcomes of 20/30 or better.
Exclusion Criteria
- Unable to tolerate ophthalmic imaging
- Any ocular or systemic conditions, that could affect VF test results, such as age-related macular degeneration, peripheral retinal disease, or severe glaucoma.
The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.
Data sourced from ClinicalTrials.gov (NCT06539715). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.